diffuse large B-cell lymphoma (DLBCL)

lion roaring
Biotech

Merck takes middle dose of ROR ADC forward into phase 3

The phase 2 lymphoma data provide more evidence of the narrow safety and efficacy window that is open to the ROR1-directed antibody-drug conjugate.
Nick Paul Taylor May 30, 2025 9:51am
Amazing landscapes of Appenzell with impressive rock formations and beautiful lakes

Merck ADC RORs into phase 3 with 100% complete response rate

Dec 9, 2024 5:03am
mountain climb steep challenge point path red flag

Regeneron seeks clarity on confirmatory trials after FDA hurdle

Mar 29, 2024 5:00am
Elm tree

ASH: Regeneron’s near-approval bispecific shines again

Dec 11, 2023 5:25am
Finger touching search engine bar

Cancer biotech IMV hunts for a deal as its cash clock ticks down

Mar 16, 2023 8:28am
target goal darts

ASH: Regeneron lymphoma med scores but safety muffles excitement

Dec 12, 2022 5:30pm